K, M, N, Q, R, V, or Y; X at position 8 is G, K, R, S, or T, or ARXIYYGWGXFDY (SEQ ID NO: 372), wherein X at position 3 is N, or M; X at position 10 is N, F, H, or Y.

2. The antibody of claim **1**, wherein:

HVR-L1 comprises the amino acid sequence of KASQNVGTAIV (SEQ ID NO: 13);

HVR-L2 comprises the amino acid sequence of SASTRYT (SEQ ID NO: 14); and

HVR-L3 comprises the amino acid sequence of QQYSSSPLT (SEQ ID NO: 15); optionally, wherein:

(a) HVR-H1 comprises the amino acid sequence of XNXXXH (SEQ ID NO: 72), wherein X at position 1 is T, A, D, E, G, H, K, N, Q, R, S, V, W, or Y; X at position 3 is N, A, F, G, H, M, R, S, V, or Y; X at position 4 is W, or F; X at position 5 is M, A, D, E, F, G, L, N, Q, R, S, T, V, or W;

(b) HVR-H2 comprises the amino acid sequence of XXHXXXXXXXXNX (SEQ ID NO: 107), wherein X at position 1 is M or F; X at position 2 is I, L, M, or V; X at position 4 is P, A, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, or W; X at position 5 is N, A, D, E, F, G, H, I, K, L, M, Q, R, S, T, V, W, or Y; X at position 6 is S, A, G, T, or V; X at position 7 is G, A, or S; X at position 8 is I, A, or V; X at position 9 is T, A, D, E, G, H, I, K, L, M, N, Q, R, S, V, W, or Y; X at position 10 is N, A, M, or S; X at position 11 is I, F, G, H, K, L, M, N, Q, R, S, T, V, W, or Y; X at position 13 is E, A, D, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y;

(c) HVR-H3 comprises the amino acid sequence of RXDXXXXXY (SEQ ID NO: 203), wherein X at position 2 is S, A, F, G, I, L, M, N, R, T, V, W, or Y; X at position 4 is G, or W; X at position 5 is T, D, E, F, H, I, K, L, M, N, Q, V, W, or Y; X at position 6 is Y, D, F, H, N, R, or W; X at position 7 is E, D, G, H, K, M, N, Q, R, V, or Y; X at position 8 is G, K, R, S, or T;

(d) HVR-H1 comprises an amino acid sequence selected from SEQ ID NOs: 41, 73-106;

(e) HVR-H2 comprises an amino acid sequence selected from SEQ ID NOs: 42, 108-202; and/or

(f) HVR-H3 comprises an amino acid sequence selected from SEQ ID NOs: 43, 204-249.

3. The antibody of claim **1**, wherein:

HVR-L1 comprises the amino acid sequence of RASQXIXXNXH (SEQ ID NO: 308), wherein X at position 5 is D, A, E, G, H, K, N, P, Q, S, or T; X at position 7 is Y, or F; X at position 8 is R, K, or Q; X at position 10 is L, I, M, or V;

HVR-L2 comprises the amino acid sequence of HAXXXXS (SEQ ID NO: 325), wherein X at position 3 is S, or E; X at position 4 is D, E, K, or Q; X at position 5 is S, H, L, R, or V; X at position 6 is I, or V; and

HVR-L3 comprises the amino acid sequence of XQGYXMPXT (SEQ ID NO: 335), wherein X at position 1 is L, G, M, or Q; X at position 5 is S, A, E, Q, or V; X at position 8 is Y, or F; optionally, wherein:

(a) HVR-L1 comprises an amino acid sequence selected from SEQ ID NOs: 37, 309-324;

(b) HVR-L2 comprises an amino acid sequence selected from SEQ ID NOs: 38, 326-334;

(c) HVR-L3 comprises an amino acid sequence selected from SEQ ID NOs: 39, 336-343.

(d) HVR-H1 comprises the amino acid sequence of or XXXGXS (SEQ ID NO: 344), wherein X at position 1 is T, A, D, E, G, H, K, M, N, Q, R, or S; X at position 2 is T, D, E, G, H, N, Q, or S; X at position 3 is Y, F, M, or Q; X at position 5 is M, I, L, or V;

(e) HVR-H2 comprises the amino acid sequence of WINTXXGVPTYAD (SEQ ID NO: 369), wherein X at position 5 is D, or E; X at position 6 is S, or T;

(f) HVR-H3 comprises the amino acid sequence of XIYYGWGXFDY (SEQ ID NO: 372), wherein X at position 1 is N, or M; X at position 8 is N, F, H, or Y;

(g) HVR-H1 comprises an amino acid sequence selected from SEQ ID NOs: 65, 345-368;

(h) HVR-H2 comprises an amino acid sequence selected from SEQ ID NOs: 66, 370-371;

(i) HVR-H3 comprises an amino acid sequence selected from SEQ ID NOs: 67, 373-376;

(j) HVR-L1 comprises the amino acid sequence of SEQ ID NO: 37, 309-324;

(k) HVR-L2 comprises the amino acid sequence of SEQ ID NO: 38, 326-334;

(l) HVR-L3 comprises the amino acid sequence of SEQ ID NO: 39, 336-343;

(m) HVR-H1 comprises an amino acid sequence selected from SEQ ID NOs: 65, 345-368;

(n) HVR-H2 comprises an amino acid sequence selected from SEQ ID NOs: 66, 370-371; and/or

(o) HVR-H3 comprises an amino acid sequence selected from SEQ ID NOs: 67, 373-376.

4. The antibody of claim **1**, wherein the antibody comprises a light chain variable domain (V_L) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 12, 16, 20, 24, 28, 32, or 36; and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 40, 44, 48, 52, 56, 60, or 64; optionally, wherein:

(a) the antibody comprises a light chain variable domain (V_L) amino acid sequence having at least 90% identity to SEQ ID NO: 12, and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to SEQ ID NO: 40; or

(b) the antibody comprises a light chain variable domain (V_L) amino acid sequence having at least 90% identity to SEQ ID NO: 36, and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to SEQ ID NO: 64.

5. The antibody of claim **1**, wherein the antibody comprises a light chain (LC) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 440, 441, 442, 443, 444, 445, or 446; and/or a heavy chain (HC) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 447, 448, 449, 450, 451, 452, 453, 484, 485, 486, 487, 488, 489, or 490; optionally, wherein:

(a) the antibody comprises a light chain (LC) amino acid sequence having at least 90% identity to SEQ ID NO: 440; and/or a heavy chain (HC) amino acid sequence having at least 90% identity to SEQ ID NO: 447, or 484; or

(b) the antibody comprises a light chain (LC) amino acid sequence having at least 90% identity to SEQ ID NO: